Severe Allograft Rejection and Autoimmune Hemolytic Anemia After Anti-PD1 Therapy in a Kidney Transplanted Patient

Transplantation. 2017 Sep;101(9):e291. doi: 10.1097/TP.0000000000001861.

Authors

Clément Deltombe¹, Claire Garandeau¹, Karine Renaudin², Maryvonne Hourmant¹

Affiliations

¹ Nephrology and Immunology Department, Institute of Transplantation in Urology and Nephrology, Nantes University Hospital, Nantes, France.
² Pathology Department, Institute of Transplantation in Urology and Nephrology, Nantes University Hospital, Nantes, France.

PMID: 29633980
DOI: 10.1097/TP.0000000000001861

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Allografts
Anemia, Hemolytic, Autoimmune / chemically induced*
Anemia, Hemolytic, Autoimmune / diagnosis
Anemia, Hemolytic, Autoimmune / immunology
Anemia, Hemolytic, Autoimmune / therapy
Antibodies, Monoclonal / adverse effects*
Antineoplastic Agents, Immunological / adverse effects*
Disease Progression
Fatal Outcome
Graft Rejection / chemically induced*
Graft Rejection / diagnosis
Graft Rejection / immunology
Graft Rejection / therapy
Humans
Immunocompromised Host
Immunosuppressive Agents / administration & dosage
Kidney Transplantation / adverse effects*
Male
Melanoma / drug therapy*
Melanoma / immunology
Melanoma / secondary
Nivolumab
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Programmed Cell Death 1 Receptor / immunology
Risk Factors
Severity of Illness Index
Skin Neoplasms / drug therapy*
Skin Neoplasms / immunology
Skin Neoplasms / pathology
Treatment Outcome

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunosuppressive Agents
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab